FBXL14

Across TCGA pan-cancer cohorts, FBXL14 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of FBXL14’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where FBXL14 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FBXL14 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

BLCA, CHOL, and STAD are the cancer types where FBXL14 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXL14 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.557	.004	6	view →
CHOL	Male	All	+1.861	<.001	5	view →
STAD	Male	II,III,IV	+0.867	<.001	5	view →
BRCA	All	II,III,IV	+0.211	.020	4	view →
THCA	All	II,III,IV	−0.584	.010	3	view →
ESCA	All	II,III,IV	+1.170	<.001	2	view →
KIRP	Female	II,III,IV	+0.699	.024	2	view →
KICH	All	All	−0.601	.003	2	view →
LIHC	All	All	+0.326	.032	2	view →
COAD	Female	All	+0.371	.030	1	view →
LUAD	Female	All	−0.281	.011	1	view →
KIRC	All	All	+0.184	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

FBXL14–BLCA

Open the BLCA breakdown →